Aridis Pharmaceuticals (ARDS) Stock Price, News & Analysis

Company Overview

Aridis Pharmaceuticals is a San Diego–based clinical-stage biotechnology company dedicated to developing immunotherapeutic products for the prevention and treatment of life-threatening bacterial and fungal infections. The company’s technology platform leverages monoclonal antibodies and inhaled antifungal formulations to address antibiotic-resistant respiratory pathogens and emerging inhalational threats. Aridis’ research focuses on targeting key virulence factors in organisms such as Pseudomonas aeruginosa and Staphylococcus aureus, with the aim of delivering novel therapeutic approaches for hospital-acquired and ventilator-associated pneumonias, catheter-related bloodstream infections and deep fungal infections of the lung.

Among the company’s pipeline candidates, AR-310 is a first-in-class inhaled monoclonal antibody against Pseudomonas aeruginosa, designed for both prophylactic and therapeutic use in patients with cystic fibrosis and those at high risk of ventilator-associated pneumonia. AR-301 is an anti–alpha-toxin antibody targeting Staphylococcus aureus bloodstream infections and antibiotic-resistant strains. AR-501, a human immunoglobulin G designed to neutralize Pseudomonas toxins, is in early-stage development for the prevention of recurrent infections. In parallel, Aridis’ inhaled liposomal amphotericin B formulation advances as a treatment for invasive pulmonary fungal infections, offering targeted delivery with reduced systemic exposure.

Aridis collaborates with U.S. government agencies, including the Biomedical Advanced Research and Development Authority (BARDA), and participates in global public–private partnerships to accelerate development of countermeasures against antimicrobial resistance. The company’s clinical trials span multiple geographies across North America and Europe, with regulatory filings planned in key markets. Aridis’ leadership team comprises seasoned biopharmaceutical executives and clinical development experts guiding the company through pivotal studies and toward potential regulatory approvals.

Key Stats

• Today's Range: $0.0001 to $0.0001
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.05
• Volume: 8,000 shs
• Average Volume: 18,414 shs
• Market Capitalization: $5.33 thousand
• P/E Ratio: 0.00
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/06/2026
• Next Earnings (Estimated): 8/19/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ARDS
• CIK: 1614067
• Web: www.aridispharma.com
• Phone: (408) 385-1742
• Fax: 408-960-3822
• Employees: 30
• Year Founded: 2003

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 0.00
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 53,321,000
• Free Float: 50,388,000
• Market Cap: $5.33 thousand
• Optionable: Not Optionable
• Beta: 44.97